← Back to Search

Dietary Supplement

Endocalyx Pro for Vascular Function in Aging (RESTORE Trial)

N/A
Waitlist Available
Led By Gary Pierce, PhD
Research Sponsored by University of Iowa
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and 12 weeks
Awards & highlights

RESTORE Trial Summary

This trial will test if 12-weeks of Endocalyx Pro supplementation can restore the glycocalyx, a thin coating that lines blood vessels, and improve blood vessel function in older adults.

Who is the study for?
This trial is for post-menopausal women aged 60-85 who can fast overnight and pause certain medications. They must be able to lie down comfortably for up to 90 minutes and sign a consent form. Exclusions include those with cardiovascular disease, neurological disorders, severe psychiatric conditions, high blood pressure, obesity (BMI > 40), allergies to specific foods, recent tobacco use, diabetes, major organ diseases or failure, current cancer treatment, autoimmune diseases like lupus or rheumatoid arthritis.Check my eligibility
What is being tested?
The study tests if Endocalyx Pro improves vascular function in older adults by restoring glycocalyx thickness—a key factor in blood vessel health. Over 12 weeks participants take this supplement while researchers measure changes using under-the-tongue imaging and ultrasound of arteries.See study design
What are the potential side effects?
Potential side effects are not detailed here but could relate to the ingredients in Endocalyx Pro which includes olive extract among others; allergic reactions may occur especially in individuals sensitive to olives, artichokes grapes or melons.

RESTORE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Brachial artery flow-mediated dilation (FMD)
Perfused boundary region (PBR)

RESTORE Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Endocalyx ProActive Control1 Intervention
Subjects will receive 6 capsules per day (3,712mg) of Endocalyx Pro (Microvascular Health Solutions, US Patent Number: 9943572), a commercially available supplement that includes a proprietary blend of glycocalyx precursors and antioxidants
Group II: PlaceboPlacebo Group1 Intervention
Subjects will ingest placebo pills

Find a Location

Who is running the clinical trial?

University of IowaLead Sponsor
454 Previous Clinical Trials
882,014 Total Patients Enrolled
3 Trials studying Aging
10,592 Patients Enrolled for Aging
Gary Pierce, PhDPrincipal InvestigatorUniversity of Iowa
2 Previous Clinical Trials
131 Total Patients Enrolled
1 Trials studying Aging
53 Patients Enrolled for Aging
~9 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top